Navigation Links
FDA Approves Merz Pharmaceuticals' Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
Date:8/2/2010

in which sustained muscle contractions cause twisting and repetitive movements or abnormal postures.  These movements, which are involuntary and sometimes painful, may affect a single muscle (focal), a group of muscles such as those in the arms, legs, or neck (segmental), or even the entire body (generalized). Symptoms can be mild or severe and dystonias may be markedly disabling.

Although dystonia is thought to be rare, it is possibly undiagnosed or misdiagnosed due to lack of specific clinical criteria. While focal dystonia, such as blepharospasm or cervical dystonia, can affect people at any age, most people first experience symptoms in middle age.

According to an epidemiology study conducted in Rochester, Minnesota, focal dystonia, which includes cervical dystonia, and may be characterized by twisting of the neck, and blepharospasm, or excessive eyelid spasm is estimated to affect 295 per million people in the U.S. Dystonias can be disabling, painful and often interfere with patients' daily activities.

About XEOMIN

In nature, Clostridium botulinum produces the toxin in association with ancillary complexing proteins. Manufacturers utilize this naturally occurring protein complex to produce therapeutic botulinum toxin products.  Now Merz introduces XEOMIN (incobotulinumtoxinA) which employs a proprietary manufacturing process that isolates the therapeutic component and eliminates these ancillary complexing proteins. XEOMIN has been formulated to have high biologic activity with a low protein load.

XEOMIN is a botulinum toxin type A that is free from complexing proteins. It is FDA approved for the treatment of adults with cervical dystonia, to decrease the severity of abnormal head position and neck pain in both botulinum toxin-naïve a
'/>"/>

SOURCE Merz Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... - New Solution That Makes ... JIN Co., Ltd. will launch JINS MEME "ACADEMIC PACK" ... yen or $5,000 (without tax /including two pairs of JINS ... a dedicated solution of "JINS MEME" to academic researchers, and ... generated by electrooculography and six-axis sensors without API. (*Physiological data ...
(Date:11/26/2014)... SAN DIEGO , Nov. 26, 2014  Aethlon ... into a definitive agreement to raise approximately $3.3 million ... is being made by one institutional healthcare focused investor. Each ... one-fifth of a common share purchase warrant. Each whole ... at a price of $0.30 for a period of ...
(Date:11/26/2014)... Nov. 26, 2014  Genomic Health, Inc. (Nasdaq: ... Chairman, Chief Executive Officer and President, will participate in ... at The New York Palace Hotel in ... 11:30 am Eastern Time (ET). To access ... call, go to the  Investor Relations  section of the ...
Breaking Medicine Technology:JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 2JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 3Aethlon Medical Announces $3.3 Million Equity Investment 2Aethlon Medical Announces $3.3 Million Equity Investment 3Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 2Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 3
... 4, 2010 /PRNewswire / -- Streamline Health ... provider of document workflow solutions for hospitals, today announced ... delivery systems in the United States, will implement Streamline ... The solution provides an automated ...
... Syringe Locking-Device Technology at HealthAchieve Conference -- JERUSALEM, November 4, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are ...
Cached Medicine Technology:Texas-Based Hospital Expands Utilization of Streamline Health Document Workflow Solutions 2Texas-Based Hospital Expands Utilization of Streamline Health Document Workflow Solutions 3Texas-Based Hospital Expands Utilization of Streamline Health Document Workflow Solutions 4Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference 2Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference 3Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference 4Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference 5Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference 6Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference 7Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference 8
(Date:11/27/2014)... 27, 2014 An inventor from Buffalo, ... fact of life, and she wants to lessen its ... later, I decided that there needed to be a ... , Easy to use and producible in design variations, ... woman’s private areas throughout the day. It avoids bad ...
(Date:11/27/2014)... HealthDay Reporter WEDNESDAY, Nov. 26, ... be safe and produces an immune system response that could ... trial results reported by the U.S. National Institutes of Health. ... the vaccine paves the way for field-testing it in the ... early as January, said Dr. Anthony Fauci, director of the ...
(Date:11/27/2014)... Las Vegas, NV (PRWEB) November 27, 2014 ... Holiday 2014 shopping season has officially launched, Emassagechair.com ... Friday and Cyber Monday Discount Event. , Negotiating ... close relationships with top massage chair brands, Emassagechair.com has ... of their best deals and biggest discounts yet. , ...
(Date:11/27/2014)... DC (PRWEB) November 27, 2014 “LAB.C” was ... which features the latest and coolest technology products available to ... conducted the product review and shared with viewers ... for iOS and Android devices. , Consumers love portability and ... Their Cable Case for the iPhone5 and 5S has ...
(Date:11/27/2014)... Philadelphia, PA (PRWEB) November 27, 2014 ... alongside volunteer Aria Health employees, prepared and donated ... to the Lutheran Settlement House , a non-profit, ... and families living in Philadelphia. The dinners were ... Settlement House Senior Center, and distributed to vulnerable ...
Breaking Medicine News(10 mins):Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Aria Health Prepares and Donates 200 Thanksgiving Dinners 2
... Ore. Researchers at Oregon Health & Science ... discovered a novel function of the peptide known ... of the trigeminal nerve. The trigeminal nerve provides ... pain, and pain associated with temporomandibular disorder, trigeminal ...
... Technologies, Inc. (Nasdaq: VNUS ), a leading ... of venous reflux disease, today announced its plans to ... to be held January 12 - 15, 2009, at ... The management speaker will be Brian Farley, President and ...
... SALT LAKE CITY, Jan. 8 In response ... nationwide, ARUP Laboratories, a national medical reference laboratory ... development, and Weber State University (WSU), ... to promote and facilitate the education of medical ...
... Education Act Mandates Label Accuracy, Truth in ... 8 In response to misleading statements ... Natural Products Association,s Executive Director and CEO, ... professional sports leagues on steroid usage, which ...
... designed to meet critical needs of patients, families ... Hospital, the flagship facility of San Diego County,s ... a multi-tiered expansion to become the premier referral ... The new 315,000-square-foot, 334-bed structure, named the Stephen ...
... 8 Over 80 percent of ... impacting not only their skin, but their self esteem as ... of benzoyl peroxide in cosmetic products in the European Union ... beauty products, consumers are taking a hard look at their ...
Cached Medicine News:Health News:ARUP Laboratories and Weber State University Team Up to Provide Laboratory Education Solutions 2Health News:ARUP Laboratories and Weber State University Team Up to Provide Laboratory Education Solutions 3Health News:ARUP Laboratories and Weber State University Team Up to Provide Laboratory Education Solutions 4Health News:Natural Products Association Advocates Strength of Dietary Supplement Law 2Health News:New Sharp Memorial Hospital Features All Private Patient Rooms, Expanded Emergency and Trauma Services and Family Waiting Areas 2Health News:New Sharp Memorial Hospital Features All Private Patient Rooms, Expanded Emergency and Trauma Services and Family Waiting Areas 3Health News:New Sharp Memorial Hospital Features All Private Patient Rooms, Expanded Emergency and Trauma Services and Family Waiting Areas 4
... Hycor Biomedical Ltd Autostat™II Rheumatoid Factor IgM ... Rheumatoid Factor IgM (RF IgM). Enzyme-linked immunosorbent ... specific IgM Rheumatoid Factor in human serum. ... can be used as an aid in ...
Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)...
... Scheimpflug Analyzer is a high precision optical ... analysis of the anterior eye segment, based ... and a Placido Disk. , GALILEI combines ... furnishes high accuracy curvature data, while Scheimpflug ...
EXTEND is an absorbable synthetic punctal implant that provides occlusion up to three months. It is packaged 20 implants per box in sizes of .0.3mm, 0.4mm, 0.5mm. A variety pack in also available w...
Medicine Products: